Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Celcuity Inc (NQ: CELC ) 14.40 +0.16 (+1.12%) Streaming Delayed Price Updated: 4:00 PM EDT, Sep 27, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Celcuity Inc < Previous 1 2 3 4 Next > Celcuity to Participate in Upcoming Needham and Canaccord Genuity Investor Conferences April 05, 2022 MINNEAPOLIS, MN / ACCESSWIRE / April 5, 2022 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing an integrated therapeutic and companion diagnostic strategy for treating... From Celcuity Inc. Via AccessWire Celcuity Inc. Reports Fourth Quarter and Full Year 2021 Financial Results, Pivotal Phase 3 Trial Design for Gedatolisib in the Treatment of Advanced Breast Cancer, and Business Updates March 23, 2022 - Finalized pivotal Phase 3 trial design following formal meetings with FDA - Received FDA Fast Track designation for gedatolisib in HR+/HER2- metastatic breast cancer - Presented updated Phase 1b data... From Celcuity Inc. Via AccessWire Exposures Product Safety The Daily Biotech Pulse: Pfizer Reports Positive Ulcerative Colitis Study Data, Novavax COVID Shot Authorized For Adolescents In India, Argenx Stock Sale March 23, 2022 Here's a roundup of top developments in the biotech space over the last 24 hours. Via Benzinga Preview: Celcuity's Earnings March 22, 2022 Celcuity (NASDAQ:CELC) is set to give its latest quarterly earnings report on Wednesday, 2022-03-23. Here's what investors need to know before the announcement. Analysts estimate... Via Benzinga The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight August 08, 2021 Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in,... Via Benzinga Exposures Product Safety Stocks That Hit 52-Week Lows On Thursday March 24, 2022 On Thursday, 112 stocks made new 52-week lows. Noteworthy Highlights From Today's 52-Week Lows: Stanley Black & Decker (NYSE:SWK) was the largest firm by market... Via Benzinga Celcuity Plans To Start Pivotal Gedatolisib Trial In Breast Cancer In 1H 2022 March 24, 2022 Via Benzinga Recap: Celcuity Q4 Earnings March 23, 2022 Celcuity (NASDAQ:CELC) reported its Q4 earnings results on Wednesday, March 23, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Celcuity... Via Benzinga Earnings Scheduled For March 23, 2022 March 23, 2022 Companies Reporting Before The Bell • AYRO (NASDAQ:AYRO) is expected to report earnings for its fourth quarter. • First Trust NASDAQ Clean Edge Smart Grid... Via Benzinga The Week Ahead In Biotech (March 20-26): Focus On Zogenix FDA Decision, Dermatology Conference Presentations & Earnings March 20, 2022 Biotech stocks rebounded along with the broader market in the week ending March 18, as risk appetite returned. Multiple conference presentations, clinical readouts and earnings news dictated sentiment... Via Benzinga Stocks That Hit 52-Week Lows On Thursday March 17, 2022 Thursday saw 34 companies set new 52-week lows. Facts of Interest About Today's 52-Week Lows: SecureWorks (NASDAQ:SCWX) was the largest company by market cap to... Via Benzinga Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2021 Financial Results and Webcast/Conference Call March 16, 2022 MINNEAPOLIS, MN / ACCESSWIRE / March 16, 2022 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing an integrated therapeutic and companion diagnostic strategy for treating... From Celcuity Inc. Via AccessWire Celcuity to Participate in the Cowen 42nd Annual Health Care Conference March 02, 2022 MINNEAPOLIS, MN / ACCESSWIRE / March 2, 2022 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing an integrated therapeutic and companion diagnostic strategy for treating... From Celcuity Inc. Via AccessWire FDA Grants Fast Track Tags To Drug Candidates For Antares Pharma, Celcuity, Celularity January 18, 2022 The FDA has granted Fast Track designation to Antares Pharma Inc's (NASDAQ: ATRS) for ATRS-1902 for adrenal crisis rescue. The development program... Via Benzinga Celcuity Receives FDA Fast Track Designation for Gedatolisib in HR+ / HER2- Metastatic Breast Cancer and Provides Corporate Update January 18, 2022 - FDA's Fast Track Designation for the pan-PI3K/mTOR inhibitor highlights potential to address the urgent need for new treatment options for breast cancer patients - On track to finalize Phase 3... From Celcuity Inc. Via AccessWire Exposures Product Safety 12 Health Care Stocks Moving In Wednesday's Intraday Session December 22, 2021 Gainers BiondVax Pharmaceuticals (NASDAQ:BVXV... Via Benzinga Celcuity Presents Updated Results of Phase 1b Study of Gedatolisib in Combination with Palbociclib and Endocrine Therapy for ER+ Advanced Breast Cancer (ABC) at the 2021 San Antonio Breast Cancer Symposium December 10, 2021 78% ORR in 3rd line patients and 63% ORR overall in patients treated with three weeks on/one week off gedatolisib dosing schedule (Arm D) MINNEAPOLIS, MN / ACCESSWIRE / December 10, 2021 / Celcuity... From Celcuity Inc. Via AccessWire Exposures COVID-19 Product Safety Celcuity to Present at the 2021 San Antonio Breast Cancer Symposium December 02, 2021 MINNEAPOLIS, MN / ACCESSWIRE / December 2, 2021 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing an integrated therapeutic and companion diagnostic strategy for treating... From Celcuity Inc. Via AccessWire Celcuity Appoints Michael Snitkovsky as VP of Program Management and David Bridge as VP of Quality Assurance and Process Development November 29, 2021 MINNEAPOLIS, MN / ACCESSWIRE / November 29, 2021 / Celcuity Inc. (Nasdaq:CELC), a clinical-stage biotechnology company pursuing an integrated therapeutic and companion diagnostic strategy for treating... From Celcuity Inc. Via AccessWire Celcuity Announces Clinical Trial Collaboration and Supply Agreement with Pfizer to Provide Ibrance(R) (palbociclib) for Planned Phase 3 Clinical Trial November 15, 2021 MINNEAPOLIS, MN / ACCESSWIRE / November 15, 2021 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing an integrated therapeutic and companion diagnostic strategy for treating... From Celcuity Inc. Via AccessWire Exposures COVID-19 Product Safety Celcuity to Participate in Upcoming Jefferies and Craig-Hallum Investor Conferences November 09, 2021 MINNEAPOLIS, MN / ACCESSWIRE / November 9, 2021 / Celcuity Inc. (Nasdaq:CELC), a clinical-stage biotechnology company pursuing an integrated therapeutic and companion diagnostic strategy for treating... From Celcuity Inc. Via AccessWire Celcuity Inc. Reports Third Quarter 2021 Financial Results and Provides Corporate Update November 08, 2021 - On track to obtain FDA feedback and initiate a Phase 3 study for gedatolisib during the first half of 2022 - Will present updated Phase 1b data during a Spotlight Poster Discussion Session at the... From Celcuity Inc. Via AccessWire Topics Intellectual Property Exposures COVID-19 Intellectual Property Product Safety Celcuity Inc. Schedules Release of Third Quarter 2021 Financial Results and Webcast/Conference Call October 29, 2021 MINNEAPOLIS, MN / ACCESSWIRE / October 29, 2021 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing an integrated companion diagnostic and therapeutic strategy for treating... From Celcuity Inc. Via AccessWire The Daily Biotech Pulse: Entasis, Dermata Spike Higher On Positive Readouts, J&J Q3 EPS Beats Estimates, Wave Life Sciences Regains Right To CNS Portfolio October 19, 2021 Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Entasis Announces Positive Data For Late-Stage Study Of SUL-DUR In... Via Benzinga Celcuity Announces Clinical Trial Collaboration with University of Rochester Wilmot Cancer Center and Puma to Study Patients with Breast Cancer Brain Metastases October 18, 2021 From Celcuity Inc. Via Business Wire Benzinga's Top Ratings Upgrades, Downgrades For September 7, 2021 September 07, 2021 Upgrades BMO Capital upgraded the previous rating for BRP Inc (NASDAQ: Via Benzinga Benzinga's Top Ratings Upgrades, Downgrades For October 8, 2021 October 08, 2021 Upgrades UBS upgraded the previous rating for Northern Trust Corp (NASDAQ: Via Benzinga Celcuity Inc. Reports Second Quarter 2021 Financial Results and Provides Corporate Update August 09, 2021 - Raised approximately $56.3 million of gross proceeds from a follow-on public offering of common stock in early July to provide funding for clinical development activities - After follow-on offering,... From Celcuity Inc. Via AccessWire Exposures COVID-19 Product Safety Celcuity to Participate in the Canaccord Genuity 41st Annual Growth Conference August 05, 2021 MINNEAPOLIS, MN / ACCESSWIRE / August 5, 2021 / Celcuity Inc. (Nasdaq:CELC), a clinical-stage biotechnology company pursuing an integrated companion diagnostic and therapeutic strategy for treating... From Celcuity Inc. Via AccessWire Celcuity Inc. Schedules Release of Second Quarter 2021 Financial Results and Webcast August 02, 2021 MINNEAPOLIS, MN / ACCESSWIRE / August 2, 2021 / Celcuity Inc. (Nasdaq:CELC), a clinical-stage biotechnology company pursuing an integrated companion diagnostic (CDx) and therapeutic strategy for... From Celcuity Inc. Via AccessWire < Previous 1 2 3 4 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.